VerityRank
Back to Rankings
Anhui Shanhe Pharmaceutical Excipients Co., Ltd.
Brand VerifiedChina

Anhui Shanhe Pharmaceutical Excipients Co., Ltd.

Shanhe Pharmacaps

Shanhe Pharmacaps is China's leading pharmaceutical excipient manufacturer and a rising force in global import substitution, headquartered in Huainan, Anhui Province, China. Founded in 2001, the company generated ¥943 million (≈$130 million) in 2025 revenue with net profit surging 47.84% year-over-year, employing 888 people. Listed on the Shenzhen Stock Exchange (SZSE: 300452), Shanhe has emerged

ChinaEst. 2001888¥943 million (2025)Core production base in Huainan Economic & Technology Development Zone, Anhui; dozens of cGMP-compliant dedicated production linesListed — SZSE: 300452Score 80

Business Nature

Shanhe Pharmacaps operates as a fully integrated manufacturer of pharmaceutical excipients, controlling the entire value chain from R&D through to finished cGMP-compliant production, validated by FDA and EU EXCIPACT certifications.

Core Business Areas

Oral Solid Dosage Excipients — Core Business
• Microcrystalline cellulose MCC for direct compression
• Carmellose sodium CMC-Na — injectable and oral grades
• Sodium stearyl fumarate — high-barrier lubricant
• Crospovidone and crosscarmellose sodium — superdisintegrants

Specialty Excipients — High-Growth Segment
• Mannitol and tartaric acid pellet cores
• Polyethylene oxide PEO for controlled-release matrices
• Co-processed excipients for direct compression

Quality Certifications — Global Market Access
• 15+ FDA DMF filings • 11 EU EXCIPACT certifications • cGMP, ISO 9001, ISO 14001

Industry Rankings

Corporate Report

Shanhe Pharmacaps is a China-based pharmaceutical excipient manufacturer headquartered in Huainan, Anhui Province. Founded in 2001 and listed on SZSE (300452), the company generated ¥943 million (~$130M) in 2025 revenue with 888 employees. Net profit surged 47.84% to ¥177M.

Business Overview

Shanhe Pharmacaps has established itself as the definitive leader in China's pharmaceutical excipient market, focusing on import substitution. The company achieved major breakthroughs in high-barrier products including sodium stearyl fumarate and injectable-grade carmellose sodium in 2025.

Key Strengths

Unmatched cost structure enabled by China's integrated chemical supply chain; world-class quality credentials including 15+ FDA DMF filings and 11 EU EXCIPACT certifications; rapidly expanding global footprint with 25%+ export growth; strong R&D pipeline; policy tailwinds from China's generic drug consistency evaluation program.

Challenges & Outlook

At ~$130M revenue, Shanhe remains a fraction of Western giants. Manufacturing concentration in Anhui creates supply chain risk. Continued growth depends on international brand-building. Shanhe Pharmacaps earns a VerityRank Score of 80/100.

VerityRank Score

80/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Huainan, Anhui Province, China

Founded

2001

Employees

888

Factories

Core production base in Huainan Economic & Technology Development Zone, Anhui; dozens of cGMP-compliant dedicated production lines

Listing

Listed — SZSE: 300452

Categories

Pharmaceutical Raw Materials & Excipients CompaniesChemical Pharmaceutical Preparations IndustryFever Reducers & Pain Relievers IndustrySkin Medications (Topical) IndustryBiological Products & Vaccines CompaniesCancer Immunotherapy IndustryInfluenza Vaccines IndustryGrowth & Rare Disease Biologics IndustryAutoimmune & Inflammatory Disease Biologics IndustryPharmaceutical Raw Materials & Excipients Manufacturers
Visit Website Listed — SZSE: 300452

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website Listed — SZSE: 300452 , Yicai — Shanhe 2025 Results
East Money — Shanhe Annual Report
Shanhe Pharmacaps Official Website

Back to Rankings